Ketoconazole Cream, 2%

Manufacturer
NuCare Pharmaceuticals,Inc.
Effective date
2021-07-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-01 22:39:27

Label at a glance#

ProductPedizolPAK
Active ingredientKETOCONAZOLE, MICONAZOLE NITRATE
Label structure24 sections

Indications and uses

Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

Dosage and administration

It is recommended that ketoconazole cream, 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment. Patients wit...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Ketoconazole cream, 2% contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, sorbitan monostearate and stearyl alcohol.

Ketoconazole is cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] piperazine and has the following structural formula:

Chemical Structure
Chemical Structure

Molecular Formula: C 26H 28Cl 2N 4O 4

Molecular Weight: 531.43

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

When ketoconazole cream, 2% was applied dermally to intact or abraded skin of beagle dogs for 28 consecutive days at a dose of 80 mg, there were no detectable plasma levels using an assay method having a lower detection limit of 2 ng/mL.

After a single topical application to the chest, back and arms of normal volunteers, systemic absorption of ketoconazole was not detected at the 5 ng/mL level in blood over a 72-hour period.

Two dermal irritancy studies, a human sensitization test, a phototoxicity study and a photoallergy study conducted in 38 male and 62 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity and no photoallergenic potential due to ketoconazole cream, 2%.

Microbiology

MICROBIOLOGY SECTION

Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the in vitro growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale) and C. tropicalis; and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare). Only those organisms listed in the INDICATIONS AND USAGE section have been proven to be clinically affected. Development of resistance to ketoconazole has not been reported.

Mode of Action

MECHANISM OF ACTION SECTION

In vitro studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not been proven.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

WARNINGS

WARNINGS SECTION

Ketoconazole cream, 2% is not for ophthalmic use.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. Hepatitis (1:10,000 reported incidence) and, at high doses, lowered testosterone and ACTH induced corticosteroid serum levels have been seen with orally administered ketoconazole; these effects have not been seen with topical ketoconazole.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames' salmonella microsomal activator assay was also negative.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels.

There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether Ketoconazole cream, 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

During clinical trials 45 (5.0%) of 905 patients treated with ketoconazole cream, 2% and 5 (2.4%) of 208 patients treated with placebo reported side effects consisting mainly of severe irritation, pruritus and stinging. One of the patients treated with ketoconazole cream developed a painful allergic reaction.

In worldwide postmarketing experience, rare reports of contact dermatitis have been associated with ketoconazole cream or one of its excipients, namely propylene glycol.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor

SPL UNCLASSIFIED SECTION

It is recommended that ketoconazole cream, 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence.

Patients with tinea versicolor usually require two weeks of treatment. Patients with tinea pedis require six weeks of treatment.

Seborrheic dermatitis

SPL UNCLASSIFIED SECTION

Ketoconazole cream, 2% should be applied to the affected area twice daily for four weeks or until clinical clearing.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ketoconazole cream, 2% is supplied in 15 g (NDC 51672-1298-1).

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1
Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

Revised: March, 2014

PK-2925-4
354

SPL UNCLASSIFIED SECTION

Drug Facts

Active Ingredient

OTC - ACTIVE INGREDIENT SECTION

Miconazole Nitrate 2% USP

Purpose

OTC - PURPOSE SECTION

Antifungal

USES

INDICATIONS & USAGE SECTION

Cures most athlete's foot ( tinea pedis) and ringworm (tinea corporis)

for effective relief of itchy,scaly skin between the toes.

Warnings

WARNINGS SECTION

For extenal use only

WHEN USING THIS PRODUCT

OTC - WHEN USING SECTION

Avoid contact with the eyes.

If irritation occurs or if there is no improvement within 4 weeks, discontinue use and consult a doctor.

Flammable

SPL UNCLASSIFIED SECTION

Do not use while smoking or near heat or flame

DO NOT USE

OTC - DO NOT USE SECTION

On children under 2 years of age unless directed by a doctor

KEEP OUT OF REACH OF CHILDREN

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

If swallowed, get medical help or contact a Poison Control Center right away .

DIRECTIONS

DOSAGE & ADMINISTRATION SECTION

clean the affected area and dry thoroughly
apply a thin layer of the product over affected area twice daily (morning and night) or as directed by a doctor
supervise children in the use of this product
for athlete’s foot: pay special attention to spaces between toes; wear well-fitting, ventilated shoes and change shoes and socks at least once daily
for athlete’s foot and ringworm, use daily for 4 weeks
if condition persists longer, consult a doctor
this product is not effective on scalp or nails.

OTHER INFORMATION

SPL UNCLASSIFIED SECTION

store at controlled room temperature 15 o-30 oC (59 o-86 oF)

INACTIVE INGREDIENTS

INACTIVE INGREDIENT SECTION

acetic acid, benzyl alcohol, isopropyl alcohol (30%), laureth-4, water

QUESTIONS OR COMMENTS

OTC - QUESTIONS SECTION

1-800-321-4576 or visit www.pedinol.com

PedizolPAK

SPL UNCLASSIFIED SECTION

Contents:

NDC 0884-0293-01

1- Pedinol Topical Antifungal 1 fl. oz. (29.57 mL)

NDC 51672-1298-1

1- Ketoconazole Cream 2% 15g

1- Foot File (with extra pads)

6- Nail Files

Ketoconazole 15g NDC 51672-1298-1

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51672-1298-1

15 g

Ketoconazole

Cream 2%

FOR DERMATOLOGIC USE ONLY.

NOT FOR OPHTHALMIC USE.

Rx only

Keep this and all medications out of the reach of children.

TARO

PRINCIPAL DISPLAY PANEL - 15 g Tube CartonPRINCIPAL DISPLAY PANEL - 15 g Tube Carton

Fungoid Tincture – 1 fl. oz. (29.57 mL) Carton NDC 0884-0293-01

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PDPPDP

PedizolPAK NDC 70859-053-01

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdppdp

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70859-053-01EA - Each70859-05326ce377a-6662-4983-9b99-cbb75317345c12019-11-12
51672-1298-1GM - Gram51672-1298d18efac5-493b-432d-a889-141da374f86f12012-07-24
51672-1298-2GM - Gram51672-1298ed634d09-35c4-49de-8c4a-140edac5f2aa12012-07-24
51672-1298-3GM - Gram51672-1298820a4a2a-778a-44fc-9192-b68f58617cf712012-07-24
0884-0293-01ML - Milliliter0884-0293c8854e7a-8786-48ac-91e1-b9ab9ded773112014-05-02

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 19 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70859-05370859-053-01
51672-129851672-1298-1
0884-02930884-0293-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 16 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075638-001KETOZOLEKETOCONAZOLE2%CREAM / TOPICALAB2002-12-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075638-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1884e616aacf4f…
2026-08-18 06:07:402026-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183f0d92c62455…
2023-05-13 08:27 UTC2023-05A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18053a50430f4f…
2023-01-26 05:58 UTC2023-01A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075638-001KETOZOLE2%CREAM / TOPICALAB2002-12-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A075638-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A075638-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075638-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075638-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075638-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075638-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075638-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075638-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075638-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075638-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075638-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075638-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075638-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075638-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075638-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075638-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075638-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075638-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075638-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075638-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075638-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075638-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075638-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A075638-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075638-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075638-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075638-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A075638-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A075638-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075638-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075638-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075638-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075638-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075638-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075638-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075638-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075638-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A075638-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075638-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A075638-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KetoconazoleKETOCONAZOLESun Pharmaceutical Industries, Inc.39b85d6a-9133-42e6-b7f8-58f045e9b9f02025-07-07Warnings, Adverse reactionsExact identifier
ndc (package): 51672-1298-1
ndc (product): 51672-1298
ndc11 (package): 51672129801
fungoid tinctureMICONAZOLE NITRATEPedinol Pharmacal, Inc.250d0a66-01d1-4aba-8f24-4cb4ca529fda2024-10-17WarningsExact identifier
ndc (package): 0884-0293-01
ndc (product): 0884-0293
ndc11 (package): 00884029301
1a17933e-b9ca-38bf-e063-6294a90a94dd9367e7df-b40a-4968-e053-2995a90ae8ac2024-06-04Warnings, Adverse reactionsExact identifier
spl set id: 9367e7df-b40a-4968-e053-2995a90ae8ac

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.